LifeSpan BioSciences to release 20,000 immunohistochemistry-validated reagent antibodies
Leader in antibody evaluation and validation expands focus to include development and sales of antibodies validated for use in immunohistochemistry
lifespan BioSciences, Inc., announced an initiative to release 20,000 immunohistochemistry-validated reagent antibodies over the next four years. The leader in immunohistochemistry (IHC) antibody validation research since 1995, LifeSpan expanded its product focus to include the development and sale of IHC-validated antibodies in Q4 2006. To date, LifeSpan has built a catalog of more than 37,000 reagent antibodies, including more than 2,000 antibodies validated for use in immunohistochemistry. The company intends to expand its IHC-validated reagent antibody catalog at the rate of 5,000 per year.
"We have a tremendous opportunity to leverage our leadership position in antibody validation to become the dominant provider of high-quality antibodies to the research and pharmaceutical communities," said Glenna Burmer, M.D., Ph.D., chief scientific officer and executive vice president of LifeSpan. "This is a very exciting time for LifeSpan. Our experience providing IHC services to over 300 pharmaceutical and biotech companies for the past 12 years positions us as uniquely capable of identifying the best antibodies for future diagnostic and therapeutic applications."
Organizations
Other news from the department manufacturing

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous